Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | USP2 | O75604 | 5/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2346510 | 0.95 | CYP3A4 (0.38) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| SCHEMBL6286545 | 0.95 | KCNH2 (0.42) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| SCHEMBL2342647 | 0.88 | KCNH2 (0.41) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| SCHEMBL2337931 | 0.87 | KCNH2 (0.43) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| Hydrochloric Acid SCHEMBL2336471 | 0.87 | KCNH2 (0.42) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| SCHEMBL2338188 | 0.85 | KCNH2 (0.44) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| SCHEMBL2343050 | 0.83 | KCNJ1 (0.41) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| SCHEMBL2344350 | 0.82 | KCNH2 (0.41) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| SCHEMBL2343855 | 0.82 | KCNH2 (0.41) | KCNH2KCNJ1TSHRUSP2CYP2C9 | |
| SCHEMBL2342064 | 0.82 | KCNH2 (0.47) | KCNH2KCNJ1TSHRUSP2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1568688-B1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARM CO LTD (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7494987-B2 | Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20060040985-A1 | Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568688-A1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040985-A1 | Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | BRD7, RBBP7, NR0B1 | KCNH2 1307/4885KCNJ1 1052/4885TSHR 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.